Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 111 articles: HTML format

Single Articles

January 2022
1. SHEPHERD JH, Ballman K, Polley MC, Campbell JD, et al
   CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
   J Clin Oncol. 2022 Jan 19:JCO2101506. doi: 10.1200/JCO.21.01506.
   PubMed     Abstract available
   
   
   
2. EISEN A, Somerfield MR, Accordino MK, Blanchette PS, et al
   Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
   J Clin Oncol. 2022 Jan 18:JCO2102647. doi: 10.1200/JCO.21.02647.
   PubMed     Abstract available
   
   
   
3. KWAN ML, Cheng RK, Iribarren C, Neugebauer R, et al
   Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.
   J Clin Oncol. 2022 Jan 13:JCO2101738. doi: 10.1200/JCO.21.01738.
   PubMed     Abstract available
   
   
   
4. JOENSUU H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, et al
   Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.
   J Clin Oncol. 2022 Jan 12:JCO2102054. doi: 10.1200/JCO.21.02054.
   PubMed     Abstract available
   
   
   
5. KHAN SA, Zhao F, Goldstein LJ, Cella D, et al
   Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
   J Clin Oncol. 2022 Jan 7:JCO2102006. doi: 10.1200/JCO.21.02006.
   PubMed     Abstract available
   
   
   
6. MAYER EL, Fesl C, Hlauschek D, Garcia-Estevez L, et al
   Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/AB
   J Clin Oncol. 2022 Jan 7:JCO2101918. doi: 10.1200/JCO.21.01918.
   PubMed     Abstract available
   
   
   December 2021
7. SCHNEIDER BP, Jiang G, Ballinger TJ, Shen F, et al
   BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
   J Clin Oncol. 2021 Dec 15:JCO2101657. doi: 10.1200/JCO.21.01657.
   PubMed     Abstract available
   
   
   
8. KROP IE, Im SA, Barrios C, Bonnefoi H, et al
   Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
   J Clin Oncol. 2021 Dec 10:JCO2100896. doi: 10.1200/JCO.21.00896.
   PubMed     Abstract available
   
   
   
9. YADAV S, Hu C, Nathanson KL, Weitzel JN, et al
   Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
   J Clin Oncol. 2021;39:3918-3926.
   PubMed     Abstract available
   
   
   
10. GIORDANO SH, Freedman RA, Somerfield MR
    Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Dec 8:JCO2102677. doi: 10.1200/JCO.21.02677.
    PubMed     Abstract available
    
    
    
11. GNANT M, Dueck AC, Frantal S, Martin M, et al
    Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    J Clin Oncol. 2021 Dec 7:JCO2102554. doi: 10.1200/JCO.21.02554.
    PubMed     Abstract available
    
    
    November 2021
12. YALA A, Mikhael PG, Strand F, Lin G, et al
    Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model.
    J Clin Oncol. 2021 Nov 12:JCO2101337. doi: 10.1200/JCO.21.01337.
    PubMed     Abstract available
    
    
    
13. WARREN LEG, Bellon JR
    Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?
    J Clin Oncol. 2021;39:3535-3540.
    PubMed     Abstract available
    
    
    
14. MCCORMICK B, Winter KA, Woodward W, Kuerer HM, et al
    Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
    J Clin Oncol. 2021;39:3574-3582.
    PubMed     Abstract available
    
    
    October 2021
15. BORGES VF
    Options for Endocrine-Refractory, Hormone Receptor-Positive Breast Cancer: Which Target and When?
    J Clin Oncol. 2021 Oct 28:JCO2101910. doi: 10.1200/JCO.21.01910.
    PubMed     Abstract available
    
    
    
16. ADEMUYIWA FO, Salyer P, Tao Y, Luo J, et al
    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    J Clin Oncol. 2021 Oct 18:JCO2101426. doi: 10.1200/JCO.21.01426.
    PubMed     Abstract available
    
    
    
17. PALMER JR, Zirpoli G, Bertrand KA, Battaglia T, et al
    A Validated Risk Prediction Model for Breast Cancer in US Black Women.
    J Clin Oncol. 2021 Oct 8:JCO2101236. doi: 10.1200/JCO.21.01236.
    PubMed     Abstract available
    
    
    September 2021
18. DE RUITER MB, Reneman L, Kieffer JM, Oldenburg HSA, et al
    Brain White Matter Microstructure as a Risk Factor for Cognitive Decline After Chemotherapy for Breast Cancer.
    J Clin Oncol. 2021 Sep 30:JCO2100627. doi: 10.1200/JCO.21.00627.
    PubMed     Abstract available
    
    
    
19. HENRY NL, Kim S, Hays RD, Diniz MA, et al
    Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.
    J Clin Oncol. 2021 Sep 23:JCO2100910. doi: 10.1200/JCO.21.00910.
    PubMed     Abstract available
    
    
    
20. SHIMANUKI Y, Shimomura A, Yoshimura K, Terakado H, et al
    Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
    J Clin Oncol. 2021 Sep 23:JCO2101757. doi: 10.1200/JCO.21.01757.
    PubMed    
    
    
    
21. SHIMOI T, Noguchi E, Sudo K, Chua YJ, et al
    Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2021 Sep 23:JCO2101537. doi: 10.1200/JCO.21.01537.
    PubMed    
    
    
    
22. TANAKA M, Shimomura A, Terakado H, Shimizu C, et al
    Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?
    J Clin Oncol. 2021 Sep 10:JCO2101716. doi: 10.1200/JCO.21.01716.
    PubMed    
    
    
    
23. JAYASEKERA J, Sparano JA, O'Neill S, Chandler Y, et al
    Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
    J Clin Oncol. 2021;39:2893-2902.
    PubMed     Abstract available
    
    
    
24. TUNG N, Desai N
    Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761.
    PubMed    
    
    
    August 2021
25. TARANTINO P, Tolaney SM, Harbeck N, Cortes J, et al
    Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go?
    J Clin Oncol. 2021 Aug 18:JCO2101059. doi: 10.1200/JCO.21.01059.
    PubMed    
    
    
    
26. BOWER JE, Partridge AH, Wolff AC, Thorner ED, et al
    Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.
    J Clin Oncol. 2021 Aug 18:JCO2100279. doi: 10.1200/JCO.21.00279.
    PubMed     Abstract available
    
    
    
27. SALERNO EA, Culakova E, Kleckner AS, Heckler CE, et al
    Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study.
    J Clin Oncol. 2021 Aug 18:JCO2003514. doi: 10.1200/JCO.20.03514.
    PubMed     Abstract available
    
    
    
28. CONNOLLY RM, Zhao F, Miller KD, Lee MJ, et al
    E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
    J Clin Oncol. 2021 Aug 6:JCO2100944. doi: 10.1200/JCO.21.00944.
    PubMed     Abstract available
    
    
    
29. TUNG NM, Zakalik D, Somerfield MR
    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
    J Clin Oncol. 2021 Aug 3:JCO2101532. doi: 10.1200/JCO.21.01532.
    PubMed     Abstract available
    
    
    July 2021
30. BURSTEIN HJ, Somerfield MR, Barton DL, Dorris A, et al
    Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101392. doi: 10.1200/JCO.21.01392.
    PubMed     Abstract available
    
    
    
31. MOY B, Rumble RB, Come SE, Davidson NE, et al
    Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
    J Clin Oncol. 2021 Jul 29:JCO2101374. doi: 10.1200/JCO.21.01374.
    PubMed     Abstract available
    
    
    
32. BODDICKER NJ, Hu C, Weitzel JN, Kraft P, et al
    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    J Clin Oncol. 2021 Jul 22:JCO2100531. doi: 10.1200/JCO.21.00531.
    PubMed     Abstract available
    
    
    
33. COBLEIGH MA, Anderson SJ, Siziopikou KP, Arthur DW, et al
    Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
    J Clin Oncol. 2021;39:2367-2374.
    PubMed     Abstract available
    
    
    
34. BRACKSTONE M, Baldassarre FG, Perera FE, Cil T, et al
    Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.
    J Clin Oncol. 2021 Jul 19:JCO2100934. doi: 10.1200/JCO.21.00934.
    PubMed     Abstract available
    
    
    
35. KAWAMURA Y, Shimomura A, Shimizu C
    Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?
    J Clin Oncol. 2021 Jul 6:JCO2101174. doi: 10.1200/JCO.21.01174.
    PubMed    
    
    
    
36. LAMBERTINI M, Blondeaux E, Bruzzone M, Perachino M, et al
    Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2021 Jul 1:JCO2100535. doi: 10.1200/JCO.21.00535.
    PubMed     Abstract available
    
    
    June 2021
37. TURAN V, Lambertini M, Lee DY, Wang E, et al
    Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.
    J Clin Oncol. 2021;39:2016-2024.
    PubMed     Abstract available
    
    
    
38. BEYER KMM, Zhou Y, Laud PW, McGinley EL, et al
    Mortgage Lending Bias and Breast Cancer Survival Among Older Women in the United States.
    J Clin Oncol. 2021 Jun 15:JCO2100112. doi: 10.1200/JCO.21.00112.
    PubMed     Abstract available
    
    
    
39. SUEMASU T, Shimomura A, Shimizu C, Hashimoto K, et al
    Regarding the Appropriate Target and Duration of Chemoprevention in Breast Cancer.
    J Clin Oncol. 2021 Jun 14:JCO2101060. doi: 10.1200/JCO.21.01060.
    PubMed    
    
    
    
40. ERIKSSON M, Eklund M, Borgquist S, Hellgren R, et al
    Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
    J Clin Oncol. 2021;39:1899-1908.
    PubMed     Abstract available
    
    
    
41. ROBSON M
    Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2.
    J Clin Oncol. 2021 Jun 9:JCO2100999. doi: 10.1200/JCO.21.00999.
    PubMed     Abstract available
    
    
    
42. GAO C, Polley EC, Hart SN, Huang H, et al
    Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.
    J Clin Oncol. 2021 Jun 8:JCO2001992. doi: 10.1200/JCO.20.01992.
    PubMed     Abstract available
    
    
    
43. MAYER IA, Zhao F, Arteaga CL, Symmans WF, et al
    Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
    J Clin Oncol. 2021 Jun 6:JCO2100976. doi: 10.1200/JCO.21.00976.
    PubMed     Abstract available
    
    
    
44. TOLANEY SM, Tayob N, Dang C, Yardley DA, et al
    Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
    J Clin Oncol. 2021 Jun 2:JCO2003398. doi: 10.1200/JCO.20.03398.
    PubMed     Abstract available
    
    
    May 2021
45. MOSKOWITZ CS, Ronckers CM, Chou JF, Smith SA, et al
    Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.
    J Clin Oncol. 2021 May 28:JCO2002244. doi: 10.1200/JCO.20.02244.
    PubMed     Abstract available
    
    
    
46. TOLANEY SM, Garrett-Mayer E, White J, Blinder VS, et al
    Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
    J Clin Oncol. 2021 May 18:JCO2003613. doi: 10.1200/JCO.20.03613.
    PubMed     Abstract available
    
    
    
47. CONNOLLY RM, Leal JP, Solnes L, Huang CY, et al
    Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.
    J Clin Oncol. 2021 May 17:JCO2100280. doi: 10.1200/JCO.21.00280.
    PubMed     Abstract available
    
    
    
48. LIN NU, Pegram M, Sahebjam S, Ibrahim N, et al
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
    J Clin Oncol. 2021 May 4:JCO2002822. doi: 10.1200/JCO.20.02822.
    PubMed     Abstract available
    
    
    
49. PRAT A, Chaudhury A, Solovieff N, Pare L, et al
    Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
    J Clin Oncol. 2021;39:1458-1467.
    PubMed     Abstract available
    
    
    April 2021
50. ALVA AS, Mangat PK, Garrett-Mayer E, Halabi S, et al
    Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    J Clin Oncol. 2021 Apr 12:JCO2002923. doi: 10.1200/JCO.20.02923.
    PubMed     Abstract available
    
    
    
51. TAIRA N, Sawaki M, Uemura Y, Saito T, et al
    Health-Related Quality of Life With Trastuzumab Monotherapy Versus Trastuzumab Plus Standard Chemotherapy as Adjuvant Therapy in Older Patients With HER2-Positive Breast Cancer.
    J Clin Oncol. 2021 Apr 9:JCO2002751. doi: 10.1200/JCO.20.02751.
    PubMed     Abstract available
    
    
    
52. LOIBL S, Marme F, Martin M, Untch M, et al
    Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
    J Clin Oncol. 2021 Apr 1:JCO2003639. doi: 10.1200/JCO.20.03639.
    PubMed     Abstract available
    
    
    
53. ANDO K, Shimomura A, Yoshimura K, Kawamura Y, et al
    What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    J Clin Oncol. 2021 Apr 1:JCO2100178. doi: 10.1200/JCO.21.00178.
    PubMed    
    
    
    March 2021
54. FASCHING PA, Yadav S, Hu C, Wunderle M, et al
    Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on Prognosis.
    J Clin Oncol. 2021 Mar 29:JCO2001200. doi: 10.1200/JCO.20.01200.
    PubMed     Abstract available
    
    
    
55. CIRUELOS EM, Rugo HS, Mayer IA, Levy C, et al
    Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
    J Clin Oncol. 2021 Mar 29:JCO2001139. doi: 10.1200/JCO.20.01139.
    PubMed     Abstract available
    
    
    
56. MCDONNELL DP, Wardell SE, Chang CY, Norris JD, et al
    Next-Generation Endocrine Therapies for Breast Cancer.
    J Clin Oncol. 2021 Mar 11:JCO2003565. doi: 10.1200/JCO.20.03565.
    PubMed    
    
    
    February 2021
57. HASHIMOTO K, Shimomura A
    Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer.
    J Clin Oncol. 2021 Feb 25:JCO2003215. doi: 10.1200/JCO.20.03215.
    PubMed    
    
    
    
58. KURIAN AW, Ward KC, Abrahamse P, Bondarenko I, et al
    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785.
    PubMed     Abstract available
    
    
    
59. PICCART M, Procter M, Fumagalli D, de Azambuja E, et al
    Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
    J Clin Oncol. 2021 Feb 4:JCO2001204. doi: 10.1200/JCO.20.01204.
    PubMed     Abstract available
    
    
    
60. SACKS GD, Morrow M
    Addressing the Dilemma of Contralateral Prophylactic Mastectomy With Behavioral Science.
    J Clin Oncol. 2021;39:269-272.
    PubMed    
    
    
    January 2021
61. BARDIA A, Kaklamani V, Wilks S, Weise A, et al
    Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
    J Clin Oncol. 2021 Jan 29:JCO2002272. doi: 10.1200/JCO.20.02272.
    PubMed     Abstract available
    
    
    
62. KORDE LA, Somerfield MR, Carey LA, Crews JR, et al
    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
    J Clin Oncol. 2021 Jan 28:JCO2003399. doi: 10.1200/JCO.20.03399.
    PubMed     Abstract available
    
    
    
63. ROSENBERGER LH, Thomas SM, Nimbkar SN, Hieken TJ, et al
    Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.
    J Clin Oncol. 2021;39:178-189.
    PubMed     Abstract available
    
    
    
64. MAGNUSON A, Sedrak MS, Gross CP, Tew WP, et al
    Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer.
    J Clin Oncol. 2021 Jan 14:JCO2002063. doi: 10.1200/JCO.20.02063.
    PubMed     Abstract available
    
    
    December 2020
65. MCNEIL CM
    Coronavirus Farewell.
    J Clin Oncol. 2020;38:4346-4348.
    PubMed    
    
    
    
66. AZIM HA JR, Ameye L, Paesmans M, Lambertini M, et al
    Reply to S. A. Narod et al.
    J Clin Oncol. 2020;38:4352-4354.
    PubMed    
    
    
    
67. MO DC, Luo PH, Huang JF, Huang SX, et al
    Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2020 Dec 17:JCO2002378. doi: 10.1200/JCO.20.02378.
    PubMed    
    
    
    
68. DEKKER TJA
    Neratinib in HER2-Positive Breast Cancer With Brain Metastases.
    J Clin Oncol. 2020 Dec 17:JCO2002385. doi: 10.1200/JCO.20.02385.
    PubMed    
    
    
    
69. DOWSETT M, Sestak I, Cuzick J
    Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2020 Dec 16:JCO2002551. doi: 10.1200/JCO.20.02551.
    PubMed    
    
    
    
70. SPARANO JA, Crager MR, Tang G, Gray RJ, et al
    Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
    J Clin Oncol. 2020 Dec 11:JCO2003007. doi: 10.1200/JCO.20.03007.
    PubMed     Abstract available
    
    
    
71. WRIGHT JL, Bellon JR
    Is the Time Right for Five-Fraction Partial Breast Irradiation?
    J Clin Oncol. 2020;38:4135-4137.
    PubMed    
    
    
    
72. BEKELMAN JE, Gupta A, Fishman E, Debono D, et al
    Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
    J Clin Oncol. 2020;38:4055-4063.
    PubMed     Abstract available
    
    
    
73. JAGSI R, Griffith KA, Vicini F, Boike T, et al
    Toward Improving Patients' Experiences of Acute Toxicity From Breast Radiotherapy: Insights From the Analysis of Patient-Reported Outcomes in a Large Multicenter Cohort.
    J Clin Oncol. 2020;38:4019-4029.
    PubMed     Abstract available
    
    
    November 2020
74. WEINSTEIN SP, Korhonen K, Cirelli C, Schnall MD, et al
    Abbreviated Breast Magnetic Resonance Imaging for Supplemental Screening of Women With Dense Breasts and Average Risk.
    J Clin Oncol. 2020;38:3874-3882.
    PubMed     Abstract available
    
    
    
75. RECHT A
    Hypofractionated Whole-Breast Irradiation: Case Closed?
    J Clin Oncol. 2020;38:3584-3586.
    PubMed    
    
    
    
76. WANG SL, Fang H, Hu C, Song YW, et al
    Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China.
    J Clin Oncol. 2020;38:3604-3614.
    PubMed     Abstract available
    
    
    
77. ANG E
    Four Women, One Evening.
    J Clin Oncol. 2020;38:3716-3718.
    PubMed    
    
    
    October 2020
78. NAROD SA, Giannakeas V
    In Response to "Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations".
    J Clin Oncol. 2020 Oct 30:JCO2002253. doi: 10.1200/JCO.20.02253.
    PubMed    
    
    
    
79. TUNG NM, Robson ME, Ventz S, Santa-Maria CA, et al
    TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    J Clin Oncol. 2020 Oct 29:JCO2002151. doi: 10.1200/JCO.20.02151.
    PubMed     Abstract available
    
    
    
80. BUUS R, Sestak I, Kronenwett R, Ferree S, et al
    Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study.
    J Clin Oncol. 2020 Oct 27:JCO2000853. doi: 10.1200/JCO.20.00853.
    PubMed     Abstract available
    
    
    
81. FERNANDEZ-MARTINEZ A, Krop IE, Hillman DW, Polley MY, et al
    Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    J Clin Oncol. 2020 Oct 23:JCO2001276. doi: 10.1200/JCO.20.01276.
    PubMed     Abstract available
    
    
    
82. DENDULURI N, Somerfield MR, Chavez-MacGregor M, Comander AH, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2020 Oct 20:JCO2002510. doi: 10.1200/JCO.20.02510.
    PubMed     Abstract available
    
    
    
83. BUCHHOLZ TA, Ali S, Hunt KK
    Reply to A. Thomsen et al.
    J Clin Oncol. 2020;38:3577.
    PubMed    
    
    
    
84. ARAOYE EF, Stearns V, Aguh C
    Considerations for the Use of Scalp Cooling Devices in Black Patients.
    J Clin Oncol. 2020;38:3575-3576.
    PubMed    
    
    
    
85. DALLA VOLTA A, Mazziotti G, Maffezzoni F, Grisanti S, et al
    Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.
    J Clin Oncol. 2020;38:3363-3366.
    PubMed    
    
    
    
86. WHELAN T, Levine M, Sussman J
    Hypofractionated Breast Irradiation: What's Next?
    J Clin Oncol. 2020;38:3245-3247.
    PubMed    
    
    
    
87. MODI S, Park H, Murthy RK, Iwata H, et al
    Reply to T.J.A. Dekker.
    J Clin Oncol. 2020;38:3351-3352.
    PubMed    
    
    
    September 2020
88. MULDER RL, Hudson MM, Bhatia S, Landier W, et al
    Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
    J Clin Oncol. 2020 Sep 29:JCO2000562. doi: 10.1200/JCO.20.00562.
    PubMed     Abstract available
    
    
    
89. WOLFF AC
    CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
    J Clin Oncol. 2020 Sep 20:JCO2002688. doi: 10.1200/JCO.20.02688.
    PubMed    
    
    
    
90. JOHNSTON SRD, Harbeck N, Hegg R, Toi M, et al
    Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
    J Clin Oncol. 2020 Sep 20:JCO2002514. doi: 10.1200/JCO.20.02514.
    PubMed     Abstract available
    
    
    
91. LIGIBEL JA
    Reply to R.T. Chlebowski et al.
    J Clin Oncol. 2020;38:3072-3073.
    PubMed    
    
    
    August 2020
92. JAFFE ES, Feldman AL, Gaulard P, Miranda RN, et al
    Reply to M. Romero et al.
    J Clin Oncol. 2020;38:2819-2820.
    PubMed    
    
    
    
93. TUNG N, Hacker MR, Garber JE
    Reply to S. Takamizawa et al.
    J Clin Oncol. 2020;38:2700-2701.
    PubMed    
    
    
    
94. TING FIL
    The Road Less Traveled: Serving the Underserved.
    J Clin Oncol. 2020;38:2597-2598.
    PubMed    
    
    
    July 2020
95. SHUMWAY DA, Momoh AO, Sabel MS, Jagsi R, et al
    Integration of Breast Reconstruction and Postmastectomy Radiotherapy.
    J Clin Oncol. 2020;38:2329-2340.
    PubMed    
    
    
    
96. MORROW M, Khan AJ
    Locoregional Management After Neoadjuvant Chemotherapy.
    J Clin Oncol. 2020;38:2281-2289.
    PubMed    
    
    
    
97. HWANG ES, Solin L
    De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer.
    J Clin Oncol. 2020;38:2230-2239.
    PubMed    
    
    
    
98. WHITE J, Thompson A, Whelan T
    Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation.
    J Clin Oncol. 2020;38:2254-2262.
    PubMed    
    
    
    
99. MAMOUNAS EP, Mitchell MP, Woodward WA
    Molecular Predictive and Prognostic Markers in Locoregional Management.
    J Clin Oncol. 2020;38:2310-2320.
    PubMed    
    
    
    
100. CATHCART-RAKE EJ, Ruddy KJ
     Smart Technology and Endocrine Therapy Adherence.
     J Clin Oncol. 2020;38:2117-2118.
     PubMed    
     
     
     June 2020
101. LLUCH A, Barrios CH, Torrecillas L, Martin M, et al
     Reply to Y. Usui et al.
     J Clin Oncol. 2020;38:2113-2114.
     PubMed    
     
     
     
102. AMBROSONE CB, Hutson AD
     Reply to E. Javor et al.
     J Clin Oncol. 2020;38:2111.
     PubMed    
     
     
     
103. ROMERO M, Melo A, Bedoya N, de la Hoz J, et al
     Should Flow Cytometry Be Considered a First Line of Study in the Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma?
     J Clin Oncol. 2020 Jun 17:JCO2000712. doi: 10.1200/JCO.20.00712.
     PubMed    
     
     
     April 2020
104. LAZZERONI M, DeCensi A
     De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ.
     J Clin Oncol. 2020;38:1252-1254.
     PubMed    
     
     
     
105. HWANG ES, Hyslop T, Hendrix LH, Duong S, et al
     Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).
     J Clin Oncol. 2020;38:1284-1292.
     PubMed     Abstract available
     
     
     
106. PAGANI O, Francis PA, Fleming GF, Walley BA, et al
     Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
     J Clin Oncol. 2020;38:1293-1303.
     PubMed     Abstract available
     
     
     
107. STEBBING J, Mainwaring PN, Curigliano G, Pegram M, et al
     Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
     J Clin Oncol. 2020;38:1070-1080.
     PubMed     Abstract available
     
     
     
108. CHIEN AJ, Tripathy D, Albain KS, Symmans WF, et al
     MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
     J Clin Oncol. 2020;38:1059-1069.
     PubMed     Abstract available
     
     
     March 2020
109. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
     Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
     J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
     PubMed     Abstract available
     
     
     
110. YANG X, Leslie G, Doroszuk A, Schneider S, et al
     Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.
     J Clin Oncol. 2020;38:674-685.
     PubMed     Abstract available
     
     
     February 2020
111. JAFFE ES, Ashar BS, Clemens MW, Feldman AL, et al
     Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.
     J Clin Oncol. 2020 Feb 11:JCO1902778. doi: 10.1200/JCO.19.02778.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: